Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Ambispective, Non-interventional, Observational, Registry Study of the Effectiveness of Elranatamab in Patients With Triple-class Exposed Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice in China(ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab)

NCT07320326 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07320326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07320326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Ambispective, Non-interventional, Observational, Registry Study of the Effectiveness of Elranatamab in Patients With Triple-class Exposed Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice in China(ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab)
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
December 30, 2025
Completion date
September 18, 2028
Enrollment
159 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tce-rrmm